3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
34
Breast
12
Sarcoma
11
Lymphoid
9
Tumor-Agnostic
2
Genitourinary
2
CNS
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Gastrointestinal
1
Conditions
Ovarian Neoplasms
1
Multiple Myeloma
1
Breast Neoplasms
1
AIDS-related Kaposi sarcoma
1
Interventions
Dexamethasone
266
Lenalidomide
159
daratumumab
137
Bortezomib
114
pomalidomide
91
Calcium Dobesilate
86
Cyclophosphamide
85
carfilzomib
77
Specimen Handling
46
isatuximab
45
fludarabine
43
Biopsy
43
belantamab mafodotin
42
Magnetic Resonance Spectroscopy
38
dexamethasone acetate
34
dexamethasone 21-phosphate
34
auricularum
33
Melphalan
33
talquetamab
29
ixazomib
27
iberdomide
27
fludarabine phosphate
24
selinexor
22
elotuzumab
21
Whole-Body Irradiation
17
X-Rays
15
venetoclax
14
Mycophenolic Acid
13
tocilizumab
12
Stem Cell Transplantation
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
liposomal doxorubicin
×
Plasma cell
×
1 year
×
Clear all
NCT05567601
2025-06-05
Doxil/Caelyx BE Study
Baxter Healthcare Corporation
Phase 1
Completed
36 enrolled